Tyrosine Kinase Inhibitor for CML: All the Same?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M
. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2019; 126(1):67-75.
PMC: 8529949.
DOI: 10.1002/cncr.32504.
View
2.
Hochhaus A, Wang J, Kim D, Kim D, Mayer J, Goh Y
. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024; 391(10):885-898.
DOI: 10.1056/NEJMoa2400858.
View
3.
Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S
. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021; 8(12):e902-e911.
DOI: 10.1016/S2352-3026(21)00333-1.
View
4.
Kantarjian H, Hughes T, Larson R, Kim D, Issaragrisil S, le Coutre P
. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(2):440-453.
PMC: 7862065.
DOI: 10.1038/s41375-020-01111-2.
View
5.
Cortes J, Saglio G, Kantarjian H, Baccarani M, Mayer J, Boque C
. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016; 34(20):2333-40.
PMC: 5118045.
DOI: 10.1200/JCO.2015.64.8899.
View